[
  {
    "ts": null,
    "headline": "Vertex Pharmaceuticals (NasdaqGS:VRTX) Advances Diabetes Portfolio Despite 2% Decline in Share Price",
    "summary": "Vertex Pharmaceuticals (NasdaqGS:VRTX) saw a notable 20.53% share price increase over the last quarter, which coincided with several key developments in its Type 1 Diabetes (T1D) initiatives. The company announced the completion of enrollment for the VX-264 and Zimislecel studies, though only Zimislecel remains on track for potential regulatory submissions following more promising outcomes. This progress, along with the recent approval of ALYFTREK in the UK for cystic fibrosis, might have...",
    "url": "https://finnhub.io/api/news?id=0586ca99e3756547dda8740be498345fc8666ca91da5dd999f50498e2f40a981",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1743268474,
      "headline": "Vertex Pharmaceuticals (NasdaqGS:VRTX) Advances Diabetes Portfolio Despite 2% Decline in Share Price",
      "id": 133558229,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "VRTX",
      "source": "Yahoo",
      "summary": "Vertex Pharmaceuticals (NasdaqGS:VRTX) saw a notable 20.53% share price increase over the last quarter, which coincided with several key developments in its Type 1 Diabetes (T1D) initiatives. The company announced the completion of enrollment for the VX-264 and Zimislecel studies, though only Zimislecel remains on track for potential regulatory submissions following more promising outcomes. This progress, along with the recent approval of ALYFTREK in the UK for cystic fibrosis, might have...",
      "url": "https://finnhub.io/api/news?id=0586ca99e3756547dda8740be498345fc8666ca91da5dd999f50498e2f40a981"
    }
  }
]